Commentary |

Newly Approved Does Not Always Mean New and Improved

Geoffrey M. Anderson, MD, PhD; David Juurlink, MD, PhD; Allan S. Detsky, MD, PhD
JAMA. 2008;299(13):1598-1600. doi:10.1001/jama.299.13.1598.
Text Size: A A A
Published online


Pharmaceutical manufacturers are in business to make money, and they make money by bringing new products to market. This statement is not a value judgment; it is a simple fact. Profits are a stimulus for innovation in the pharmaceutical industry, and innovation is the basis of progress and improvement in health care.

The most profitable products for these companies are “blockbuster” drugs, which are commonly defined as drugs that generate more than $1 billion in revenue annually. Selective inhibitors of cyclooxygenase type 2 (“coxibs”) and atypical antipsychotics are 2 examples of drug classes that produced blockbuster sales. Recent controversies around both drug classes highlight some of the difficulties inherent in balancing the promise of innovation and improved care against real-world safety and effectiveness. Much has been made about the need for reform of regulatory agencies to ensure that the public is protected from unsafe drugs while still being afforded timely access to efficacious new ones.1,2 In this Commentary, we argue that regulatory reform alone is an insufficient step toward improving drug safety.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 7

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario